An Open-label, 2-Period, Fixed-sequence, Phase 1 Study in Healthy Volunteers to Evaluate the Effect of Itraconazole, a Potent CYP3A Inhibitor, on the Pharmacokinetics of IW-1973
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2019
Price : $35 *
At a glance
- Drugs Praliciguat (Primary) ; Itraconazole
- Indications Cardiovascular disorders; Diabetic nephropathies; Heart failure; Hypertension in diabetes; Pulmonary arterial hypertension
- Focus Pharmacokinetics
- Sponsors Ironwood Pharmaceuticals
- 19 Jul 2018 Status changed from active, no longer recruiting to completed.
- 07 Jun 2018 Planned End Date changed from 2 Jul 2018 to 9 Jul 2018.
- 07 Jun 2018 Planned primary completion date changed from 2 Jul 2018 to 9 Jul 2018.